Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.

Suppression of abnormal karyotype predicts superior survival in multiple myeloma. Leukemia (2008) 1.97

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood (2011) 1.61

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood (2009) 1.13

Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica (2013) 1.10

The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol (2007) 1.09

Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia (2013) 1.05

The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol (2011) 0.86

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use. BMC Med Genomics (2014) 0.81

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. BMC Bioinformatics (2015) 0.79

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk Lymphoma (2017) 0.77

The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther (2016) 0.75

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. Oncotarget (2016) 0.75

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol (2007) 18.32

A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11

International staging system for multiple myeloma. J Clin Oncol (2005) 11.29

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67

The molecular classification of multiple myeloma. Blood (2006) 8.77

Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med (2006) 7.89

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08

IRF4 addiction in multiple myeloma. Nature (2008) 6.27

The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01

Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol (2005) 4.33

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04

The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 3.94

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60

Fusarium infections in immunocompromised patients. Clin Microbiol Rev (2007) 3.44

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood (2010) 3.41

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol (2007) 3.41

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) 3.22

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood (2006) 3.17

Multiple myeloma: clinical review and diagnostic imaging. Radiology (2004) 3.12

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis (2010) 3.07

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 2.95

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol (2007) 2.93

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood (2007) 2.91